Uridine reduces rotation induced by L-dopa and methamphetamine in 6-OHDA-treated rats.
The pyrimidine nucleoside uridine may reduce side effects associated with antipsychotic medication by interacting with dopamine or GABA neurotransmission. Male Sprague-Dawley rats were used to investigate coadministration of uridine with agents that alter food intake (amphetamine, haloperidol, and chlordiazepoxide) and locomotor activity (methamphetamine and L-dopa). Results indicated that chronic uridine [32.0 mg/kg, intraperitoneally (IP)] alone did not alter milk intake or reduction of milk intake induced by amphetamine (dose range 0.5-2.0 mg/kg, IP) or haloperidol (0.125-1.0 mg/kg, IP), nor did it alter the biphasic response induced by chlordiazepoxide (5.0-40.0 mg/kg, IP). However, uridine-treated animals with unilateral striatal lesions exhibited no rotational behavior in the absence of drug challenge, but showed decreased rotation induced by the dopamine agonist, L-dopa (50.0-200.0 mg/kg, IP) compared with controls. In addition, uridine-treated rats exhibited reduced rotation after repeated injections of methamphetamine (4.0 mg/kg, IP) in contrast to increasingly greater rotation observed in control animals. These results are further evidence that chronic uridine may alter drug-induced dopaminergic activity without exerting effects itself.
Myers
C S
CS
Department of Psychology, Rutgers University, New Brunswick, NJ 08903, USA.
Fisher
H
H
Wagner
G C
GC
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D016627:Oxidopamine / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012399:Rotation; D014529:Uridine / Q000494:pharmacology*
D008694:Methamphetamine; D007980:Levodopa; D016627:Oxidopamine; D006220:Haloperidol; D014529:Uridine